About Tibotec
|
Tibotec is changing people's lives and improving public health by fighting infectious diseases worldwide. We are achieving this by delivering innovative therapeutic and diagnostic solutions that provide significant benefits to patients. Tibotec recognizes its responsibility to collaborate in the international response to HIV/AIDS, a challenge which cannot be separated from the fight for gender equality and poverty reduction. For more information on our credo and our giving, please click here. For more information on Tibotec's multi-pronged approach to the HIV/AIDS pandemic in the developing world, please click here.
Visit our home page to find information on people and facilities in the various regions of the world and all of Tibotec's web offerings, including a global map that is searchable by region and links to our disease portals. Or click here to download a copy of the Tibotec Infectious Disease & Vaccine Corporate Brochure.
Tibotec R&D is dedicated to the discovery and development of innovative new drugs for HIV/AIDS and other infectious diseases of high unmet medical need. Tibotec was established in 1994 by Rudi Pauwels as a drug discovery laboratory. In 1995, Virco was established as a spin-off to improve the management of HIV/AIDS with innovative, new molecular diagnostic tools for HIV resistance testing that would better inform the treatment decisions made by physicians. In April 2002, Tibotec and Virco were acquired by Johnson & Johnson.
For further information on Tibotec's compounds, click on:
HIV:
-
TMC114 (darunavir), a protease inhibitor (PI),
-
TMC125 (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI),
-
TMC278, (rilpivirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI).
-
TMC120, (dapivirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI), now being developed by the International Partnership for Microbicides (IPM) as a vaginal microbicide.
TB:
HCV:
-
VX950 (telaprevir), a protease inhibitor (PI),
-
TMC435 a protease inhibitor (PI).
|
|
|
